- Home
- CMMB vs PLUR Comparison
CMMB vs PLUR Comparison
Compare CMMB & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PLUR
- Stock Information
- Founded
- CMMB 2004
- PLUR 2001
- Country
- CMMB Israel
- PLUR Israel
- Employees
- CMMB N/A
- PLUR N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMMB Health Care
- PLUR Health Care
- Exchange
- CMMB Nasdaq
- PLUR Nasdaq
- Market Cap
- CMMB 23.6M
- PLUR 26.7M
- IPO Year
- CMMB N/A
- PLUR N/A
- Fundamental
- Price
- CMMB $1.20
- PLUR $6.75
- Analyst Decision
- CMMB Strong Buy
- PLUR
- Analyst Count
- CMMB 2
- PLUR 0
- Target Price
- CMMB $9.00
- PLUR N/A
- AVG Volume (30 Days)
- CMMB 167.2K
- PLUR 24.8K
- Earning Date
- CMMB 05-08-2025
- PLUR 05-09-2025
- Dividend Yield
- CMMB N/A
- PLUR N/A
- EPS Growth
- CMMB N/A
- PLUR N/A
- EPS
- CMMB N/A
- PLUR N/A
- Revenue
- CMMB N/A
- PLUR $678,000.00
- Revenue This Year
- CMMB N/A
- PLUR $472.39
- Revenue Next Year
- CMMB N/A
- PLUR $254.29
- P/E Ratio
- CMMB N/A
- PLUR N/A
- Revenue Growth
- CMMB N/A
- PLUR 89.92
- 52 Week Low
- CMMB $0.58
- PLUR $3.33
- 52 Week High
- CMMB $2.55
- PLUR $6.60
- Technical
- Relative Strength Index (RSI)
- CMMB 50.27
- PLUR 80.65
- Support Level
- CMMB $1.08
- PLUR $3.36
- Resistance Level
- CMMB $1.25
- PLUR $3.92
- Average True Range (ATR)
- CMMB 0.11
- PLUR 0.48
- MACD
- CMMB 0.04
- PLUR 0.24
- Stochastic Oscillator
- CMMB 83.65
- PLUR 90.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.